Th2 Cytokines (Interleukin-5 and -9) Polymorphism Affects the Response to Anti-TNF Treatment in Polish Patients with Ankylosing Spondylitis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Nov 11

PMID 36361964

Authors

Sylwia Bialy

Milena Iwaszko

Jerzy Swierkot

Bartosz Bugaj

Katarzyna Kolossa

Slawomir Jeka

Katarzyna Bogunia-Kubik

Affiliations

Soon will be listed here.

Abstract

Ankylosing spondylitis (AS) is an inflammatory disease that belongs to the spondyloarthritis family. IL-5 and IL-9 belong to the group of Th2 cytokines of anti-inflammatory nature. Polymorphisms in their coding genes have been so far associated with various inflammatory diseases, but there are no reports regarding their involvement in AS pathogenesis to date. The purpose of the study was to investigate relationships between IL5 and IL9 genetic variants with AS susceptibility, clinical parameters as well as response to therapy with TNF inhibitors. In total 170 patients receiving anti-TNF therapy and 218 healthy controls were enrolled in the study. The genotyping of IL5 rs2069812 (A > G) and IL9 rs2069885 (G > A) single nucleotide polymorphisms was performed using the Real-Time PCR method based on LightSNiP kits assays. The present study demonstrated significant relationships between IL5 rs2069812 and IL9 rs2069885 polymorphisms and response to anti-TNF therapy. Presence of the IL5 rs2069812 A allele in patients positively correlated with better response to treatment (p = 0.022). With regard to IL9 rs2069885, patients carrying the A allele displayed better outcomes in anti-TNF therapy (p = 0.046). In addition, IL5 rs2069812 A and IL9 rs2069885 A alleles were associated with lower CRP and VAS values. The obtained results may indicate a significant role for IL-5 and IL-9 in the course of AS and response to anti-TNF therapy.

Citing Articles

An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis.

Dolcetti E, Buttari F, Bruno A, Azzolini F, Gilio L, Borrelli A Int J Mol Sci. 2024; 25(16).

PMID: 39201794 PMC: 11354457. DOI: 10.3390/ijms25169108.

Environmental and Genetic Determinants of Ankylosing Spondylitis.

Bilski R, Kaminski P, Kupczyk D, Jeka S, Baszynski J, Tkaczenko H Int J Mol Sci. 2024; 25(14).

PMID: 39063056 PMC: 11277374. DOI: 10.3390/ijms25147814.

Locus of (IL-9) control: IL9 epigenetic regulation in cellular function and human disease.

Son A, Baral I, Falduto G, Schwartz D Exp Mol Med. 2024; 56(6):1331-1339.

PMID: 38825637 PMC: 11263352. DOI: 10.1038/s12276-024-01241-y.

Analysis of IL-1β, TGF-β, IL-5, ACE, PTPN22 gene polymorphisms, and gene expression levels in Turkish children with IgA vasculitis.

Taskin R, Aydin I, Aytac G, Imamoglu S, Conkar Tuncay S, Bulut I Mol Biol Rep. 2023; 51(1):15.

PMID: 38085361 DOI: 10.1007/s11033-023-08944-x.

References

Vilkeviciute A, Cebatoriene D, Kriauciuniene L, Zemaitiene R, Liutkeviciene R . and Single-Nucleotide Variants and Serum Levels in Age-Related Macular Degeneration in the Caucasian Population. Mediators Inflamm. 2021; 2021:6622934. PMC: 8057879. DOI: 10.1155/2021/6622934. View

Chen Z, Andreev D, Oeser K, Krljanac B, Hueber A, Kleyer A . Th2 and eosinophil responses suppress inflammatory arthritis. Nat Commun. 2016; 7:11596. PMC: 4899615. DOI: 10.1038/ncomms11596. View

Iwaszko M, Wielinska J, Swierkot J, Kolossa K, Sokolik R, Bugaj B . Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients. Front Immunol. 2021; 12:631603. PMC: 8226138. DOI: 10.3389/fimmu.2021.631603. View

Frazer K, Ueda Y, Zhu Y, Gifford V, Garofalo M, Mohandas N . Computational and biological analysis of 680 kb of DNA sequence from the human 5q31 cytokine gene cluster region. Genome Res. 1997; 7(5):495-512. DOI: 10.1101/gr.7.5.495. View

Zhu W, Liu N, Zhao Y, Jia H, Cui B, Ning G . Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves' disease. J Endocrinol Invest. 2010; 33(10):751-5. DOI: 10.1007/BF03346682. View

Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X . Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood. 2010; 117(2):585-90. PMC: 3031482. DOI: 10.1182/blood-2010-07-295097. View

Iwaszko M, Bialy S, Bogunia-Kubik K . Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis. Cells. 2021; 10(11). PMC: 8616130. DOI: 10.3390/cells10113000. View

Inoue N, Watanabe M, Morita M, Tatusmi K, Hidaka Y, Akamizu T . Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol. 2011; 163(3):318-23. PMC: 3048614. DOI: 10.1111/j.1365-2249.2010.04306.x. View

Schoenbeck S, McKenzie D, Kagnoff M . Interleukin 5 is a differentiation factor for IgA B cells. Eur J Immunol. 1989; 19(6):965-9. DOI: 10.1002/eji.1830190602. View

10.

Carter L, Swain S . From naive to memory. Development and regulation of CD4+ T cell responses. Immunol Res. 1998; 18(1):1-13. DOI: 10.1007/BF02786509. View

11.

Kopf M, Brombacher F, Hodgkin P, Ramsay A, Milbourne E, Dai W . IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 1996; 4(1):15-24. DOI: 10.1016/s1074-7613(00)80294-0. View

12.

Ciccia F, Guggino G, Ferrante A, Cipriani P, Giacomelli R, Triolo G . Interleukin-9 and T helper type 9 cells in rheumatic diseases. Clin Exp Immunol. 2016; 185(2):125-32. PMC: 4954997. DOI: 10.1111/cei.12807. View

13.

Punnonen J, Aversa G, Cocks B, McKenzie A, Menon S, Zurawski G . Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A. 1993; 90(8):3730-4. PMC: 46375. DOI: 10.1073/pnas.90.8.3730. View

14.

Mestiri S, Zaaber I, Inoubli O, Abid N, Omrani A, Nejehi H . Association of cytokine Th2 gene polymorphisms with autoimmune thyroid diseases in Tunisian population. Int J Immunogenet. 2020; 47(3):294-308. DOI: 10.1111/iji.12472. View

15.

Murphy J, Young I . IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam Horm. 2006; 74:1-30. DOI: 10.1016/S0083-6729(06)74001-8. View

16.

Dantas A, Lopes Marques C, da Rocha Junior L, Brayner Cavalcanti M, Goncalves S, Cardoso P . Increased Serum Interleukin-9 Levels in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Pathogenic Role or Just an Epiphenomenon?. Dis Markers. 2015; 2015:519638. PMC: 4452366. DOI: 10.1155/2015/519638. View

17.

Dent L, Strath M, Mellor A, Sanderson C . Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990; 172(5):1425-31. PMC: 2188679. DOI: 10.1084/jem.172.5.1425. View

18.

Pasvenskaite A, Liutkeviciene R, Gedvilaite G, Vilkeviciute A, Liutkevicius V, Uloza V . The Role of Polymorphisms and Serum IL-9 Levels in Carcinogenesis and Survival Rate for Laryngeal Squamous Cell Carcinoma. Cells. 2021; 10(3). PMC: 8001846. DOI: 10.3390/cells10030601. View

19.

Diny N, Rose N, cihakova D . Eosinophils in Autoimmune Diseases. Front Immunol. 2017; 8:484. PMC: 5406413. DOI: 10.3389/fimmu.2017.00484. View

20.

Yamamoto N, Sugiura H, Tanaka K, Uehara M . Heterogeneity of interleukin 5 genetic background in atopic dermatitis patients: significant difference between those with blood eosinophilia and normal eosinophil levels. J Dermatol Sci. 2003; 33(2):121-6. DOI: 10.1016/s0923-1811(03)00149-x. View